当前位置：
X-MOL 学术
›
Acc. Chem. Res.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Chemical Strategies to Enhance the Therapeutic Efficacy of Toll-like Receptor Agonist Based Cancer Immunotherapy.
Accounts of Chemical Research ( IF 16.4 ) Pub Date : 2020-09-23 , DOI: 10.1021/acs.accounts.0c00337 Sang Nam Lee 1 , Seung Mo Jin 1 , Hong Sik Shin 1 , Yong Taik Lim 1
Accounts of Chemical Research ( IF 16.4 ) Pub Date : 2020-09-23 , DOI: 10.1021/acs.accounts.0c00337 Sang Nam Lee 1 , Seung Mo Jin 1 , Hong Sik Shin 1 , Yong Taik Lim 1
Affiliation
|
Recent developments in the fields of biomedical chemistry and immune bioengineering have enabled innovative therapeutic approaches that can enhance the efficacy, accuracy, and safety of cancer immunotherapy. Among the numerous strategies utilized in cancer immunotherapy, Toll-like receptor (TLR) agonist-based approaches have been studied for a long time since they trigger the innate immune system and generate antigen-specific T cell responses to fight against tumors. In addition to these immunostimulatory functions, TLR agonists also contribute to the reprogramming of immune suppressive tumor microenvironments. Although TLR agonists are now being intensively studied in clinical trials due to their substantial immunomodulatory properties, they still show a low therapeutic index. Nonspecific and random stimulation of various immune cells produces excess levels of proinflammatory cytokines, resulting in cytokine storms and chronic diseases. Therefore, the development of chemical strategies to enhance the therapeutic efficacy as well as the safety of TLR agonist-based immunotherapy is essential and in high demand.
中文翻译：
化学策略，以提高基于Toll样受体激动剂的癌症免疫治疗的疗效。
生物医学化学和免疫生物工程领域的最新发展使创新的治疗方法得以实现，从而可以增强癌症免疫疗法的功效，准确性和安全性。在癌症免疫疗法中使用的众多策略中，基于Toll样受体（TLR）激动剂的方法已被研究了很长时间，因为它们触发先天免疫系统并产生抗原特异性T细胞应答以对抗肿瘤。除这些免疫刺激功能外，TLR激动剂还有助于免疫抑制性肿瘤微环境的重编程。尽管由于其大量的免疫调节特性，目前正在临床试验中对TLR激动剂进行深入研究，但它们仍显示出较低的治疗指数。各种免疫细胞的非特异性和随机刺激会产生过量的促炎细胞因子，从而导致细胞因子风暴和慢性疾病。因此，开发化学策略以提高基于TLR激动剂的免疫疗法的治疗功效以及安全性是必不可少的并且是高度需求的。
更新日期：2020-10-21
中文翻译：
化学策略，以提高基于Toll样受体激动剂的癌症免疫治疗的疗效。
生物医学化学和免疫生物工程领域的最新发展使创新的治疗方法得以实现，从而可以增强癌症免疫疗法的功效，准确性和安全性。在癌症免疫疗法中使用的众多策略中，基于Toll样受体（TLR）激动剂的方法已被研究了很长时间，因为它们触发先天免疫系统并产生抗原特异性T细胞应答以对抗肿瘤。除这些免疫刺激功能外，TLR激动剂还有助于免疫抑制性肿瘤微环境的重编程。尽管由于其大量的免疫调节特性，目前正在临床试验中对TLR激动剂进行深入研究，但它们仍显示出较低的治疗指数。各种免疫细胞的非特异性和随机刺激会产生过量的促炎细胞因子，从而导致细胞因子风暴和慢性疾病。因此，开发化学策略以提高基于TLR激动剂的免疫疗法的治疗功效以及安全性是必不可少的并且是高度需求的。
京公网安备 11010802027423号